Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.

Positive results from ADEPT phase 2/3 study of Dupixent in adults with moderate-to-severe bullous pemphigoid presented at AAD: Paris Tuesday, March 11, 2025, 14:00 Hrs [IST] Posit ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Abrocitinib was efficacious and safe in patients with atopic dermatitis who did and who did not respond to prior treatment with dupilumab.

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

The FDA is expected to decide on treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine.

Across six asthma biologics, adherence differed by the therapy given and was often low or irregular based on three adherence measures, according to a presentation here.This cross-sectional cohort ...